Investment Trust Insider - Opening the door to investment trusts

Register to get unlimited access to our investor forum and all editorial content, including our e-zine and weekly email. Registration is free and only takes a minute.

Dividends and drugs prove a potent mix for IBT

International Biotechnology Trust (IBT) triumphed in an eclectic category at the Citywire Investment Trust Awards, seeing off competition from property, technology and environmental funds to be crowned best Specialist Equities trust.

Our awards analysed trusts' three-year risk-adjusted performance, and on that measure, IBT has performed impressively.

But that performance has been amplified for shareholders thanks to a steady rerating of the shares since the announcement last year that it would pay a 4% dividend.

Having traded at a discount of more than 20% three years ago, the shares have this month establish a small premium to net asset value.

In this short video, manager Ailsa Craig reflects on a strong year for the trust and discusses a possible catalyst for the next leg of the biotechnology sector's rally.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.